INTI

SEC source: 0000899243-17-007150 · doc4.xml · nonDerivative · entry 2

Ono Richard Dana · CIK 0001595989 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 181,200

SEC source: 0000899243-17-007150 · doc4.xml · nonDerivative · entry 1

Ono Richard Dana · CIK 0001595989 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The RSUs were issued to the reporting person on July 18, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms.

SEC source: 0001144204-16-134828 · v453196_4.xml · derivative · entry 6

Mayne Pharma Ventures Pty Ltd · CIK 0001611535 · 10% owner

Mayne Pharma International Pty Ltd · CIK 0001611534 · 10% owner

Mayne Pharma Group Ltd · CIK 0001560183 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,504,236

Underlying: Common Stock · 4,860,000 shares

Expires not disclosed

F3 · security: On November 15, 2016, Mayne Ventures acquired 4,860,000 shares of Common Stock for an aggregate purchase price of $583,200 through the partial exercise of a warrant (at a per share exercise price of $0.12) that was issued by the Issuer to Mayne Ventures on May 25, 2016 (the "2016 Warrant"). 23,504,236 shares of Common Stock remain issuable upon exercise of the 2016 Warrant. The 2016 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time on or prior to May 25, 2021.

F3 · kind: On November 15, 2016, Mayne Ventures acquired 4,860,000 shares of Common Stock for an aggregate purchase price of $583,200 through the partial exercise of a warrant (at a per share exercise price of $0.12) that was issued by the Issuer to Mayne Ventures on May 25, 2016 (the "2016 Warrant"). 23,504,236 shares of Common Stock remain issuable upon exercise of the 2016 Warrant. The 2016 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time on or prior to May 25, 2021.

F3 · shares: On November 15, 2016, Mayne Ventures acquired 4,860,000 shares of Common Stock for an aggregate purchase price of $583,200 through the partial exercise of a warrant (at a per share exercise price of $0.12) that was issued by the Issuer to Mayne Ventures on May 25, 2016 (the "2016 Warrant"). 23,504,236 shares of Common Stock remain issuable upon exercise of the 2016 Warrant. The 2016 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time on or prior to May 25, 2021.

F3 · price: On November 15, 2016, Mayne Ventures acquired 4,860,000 shares of Common Stock for an aggregate purchase price of $583,200 through the partial exercise of a warrant (at a per share exercise price of $0.12) that was issued by the Issuer to Mayne Ventures on May 25, 2016 (the "2016 Warrant"). 23,504,236 shares of Common Stock remain issuable upon exercise of the 2016 Warrant. The 2016 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time on or prior to May 25, 2021.

F3 · derivative.exercise_date: On November 15, 2016, Mayne Ventures acquired 4,860,000 shares of Common Stock for an aggregate purchase price of $583,200 through the partial exercise of a warrant (at a per share exercise price of $0.12) that was issued by the Issuer to Mayne Ventures on May 25, 2016 (the "2016 Warrant"). 23,504,236 shares of Common Stock remain issuable upon exercise of the 2016 Warrant. The 2016 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time on or prior to May 25, 2021.

F3 · derivative.expiration_date: On November 15, 2016, Mayne Ventures acquired 4,860,000 shares of Common Stock for an aggregate purchase price of $583,200 through the partial exercise of a warrant (at a per share exercise price of $0.12) that was issued by the Issuer to Mayne Ventures on May 25, 2016 (the "2016 Warrant"). 23,504,236 shares of Common Stock remain issuable upon exercise of the 2016 Warrant. The 2016 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time on or prior to May 25, 2021.

F3 · derivative.underlying_shares: On November 15, 2016, Mayne Ventures acquired 4,860,000 shares of Common Stock for an aggregate purchase price of $583,200 through the partial exercise of a warrant (at a per share exercise price of $0.12) that was issued by the Issuer to Mayne Ventures on May 25, 2016 (the "2016 Warrant"). 23,504,236 shares of Common Stock remain issuable upon exercise of the 2016 Warrant. The 2016 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time on or prior to May 25, 2021.

F3 · balance_after: On November 15, 2016, Mayne Ventures acquired 4,860,000 shares of Common Stock for an aggregate purchase price of $583,200 through the partial exercise of a warrant (at a per share exercise price of $0.12) that was issued by the Issuer to Mayne Ventures on May 25, 2016 (the "2016 Warrant"). 23,504,236 shares of Common Stock remain issuable upon exercise of the 2016 Warrant. The 2016 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time on or prior to May 25, 2021.

F4 · ownership.direct: These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd ("Mayne International") and Mayne Pharma Group Limited ("Mayne Group"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer.

SEC source: 0001144204-16-134828 · v453196_4.xml · derivative · entry 5

Mayne Pharma Ventures Pty Ltd · CIK 0001611535 · 10% owner

Mayne Pharma International Pty Ltd · CIK 0001611534 · 10% owner

Mayne Pharma Group Ltd · CIK 0001560183 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 333 shares

Expires not disclosed

F2 · security: On November 15, 2016, Mayne Ventures acquired 333 shares of Common Stock for an aggregate purchase price of $24.98 through the exercise of a warrant (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015 (the "2015 Warrant"). No shares of Common Stock remain issuable upon exercise of the 2015 Warrant.

F2 · kind: On November 15, 2016, Mayne Ventures acquired 333 shares of Common Stock for an aggregate purchase price of $24.98 through the exercise of a warrant (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015 (the "2015 Warrant"). No shares of Common Stock remain issuable upon exercise of the 2015 Warrant.

F2 · shares: On November 15, 2016, Mayne Ventures acquired 333 shares of Common Stock for an aggregate purchase price of $24.98 through the exercise of a warrant (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015 (the "2015 Warrant"). No shares of Common Stock remain issuable upon exercise of the 2015 Warrant.

F2 · price: On November 15, 2016, Mayne Ventures acquired 333 shares of Common Stock for an aggregate purchase price of $24.98 through the exercise of a warrant (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015 (the "2015 Warrant"). No shares of Common Stock remain issuable upon exercise of the 2015 Warrant.

F2 · derivative.exercise_date: On November 15, 2016, Mayne Ventures acquired 333 shares of Common Stock for an aggregate purchase price of $24.98 through the exercise of a warrant (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015 (the "2015 Warrant"). No shares of Common Stock remain issuable upon exercise of the 2015 Warrant.

F2 · derivative.expiration_date: On November 15, 2016, Mayne Ventures acquired 333 shares of Common Stock for an aggregate purchase price of $24.98 through the exercise of a warrant (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015 (the "2015 Warrant"). No shares of Common Stock remain issuable upon exercise of the 2015 Warrant.

F2 · derivative.underlying_shares: On November 15, 2016, Mayne Ventures acquired 333 shares of Common Stock for an aggregate purchase price of $24.98 through the exercise of a warrant (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015 (the "2015 Warrant"). No shares of Common Stock remain issuable upon exercise of the 2015 Warrant.

F2 · balance_after: On November 15, 2016, Mayne Ventures acquired 333 shares of Common Stock for an aggregate purchase price of $24.98 through the exercise of a warrant (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015 (the "2015 Warrant"). No shares of Common Stock remain issuable upon exercise of the 2015 Warrant.

F4 · ownership.direct: These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd ("Mayne International") and Mayne Pharma Group Limited ("Mayne Group"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer.

SEC source: 0001144204-16-134828 · v453196_4.xml · derivative · entry 4

Mayne Pharma Ventures Pty Ltd · CIK 0001611535 · 10% owner

Mayne Pharma International Pty Ltd · CIK 0001611534 · 10% owner

Mayne Pharma Group Ltd · CIK 0001560183 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,750,569 shares

Expires not disclosed

F1 · security: On November 15, 2016, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") acquired 4,750,569 shares of Common Stock for an aggregate purchase price of $417,099.96 through the exercise of a warrant (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the "2014 Warrant"). Following such exercise, no shares of Common Stock remain issuable upon exercise of the 2014 Warrant.

F1 · kind: On November 15, 2016, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") acquired 4,750,569 shares of Common Stock for an aggregate purchase price of $417,099.96 through the exercise of a warrant (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the "2014 Warrant"). Following such exercise, no shares of Common Stock remain issuable upon exercise of the 2014 Warrant.

F1 · shares: On November 15, 2016, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") acquired 4,750,569 shares of Common Stock for an aggregate purchase price of $417,099.96 through the exercise of a warrant (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the "2014 Warrant"). Following such exercise, no shares of Common Stock remain issuable upon exercise of the 2014 Warrant.

F1 · price: On November 15, 2016, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") acquired 4,750,569 shares of Common Stock for an aggregate purchase price of $417,099.96 through the exercise of a warrant (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the "2014 Warrant"). Following such exercise, no shares of Common Stock remain issuable upon exercise of the 2014 Warrant.

F1 · derivative.exercise_date: On November 15, 2016, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") acquired 4,750,569 shares of Common Stock for an aggregate purchase price of $417,099.96 through the exercise of a warrant (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the "2014 Warrant"). Following such exercise, no shares of Common Stock remain issuable upon exercise of the 2014 Warrant.

F1 · derivative.expiration_date: On November 15, 2016, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") acquired 4,750,569 shares of Common Stock for an aggregate purchase price of $417,099.96 through the exercise of a warrant (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the "2014 Warrant"). Following such exercise, no shares of Common Stock remain issuable upon exercise of the 2014 Warrant.

F1 · derivative.underlying_shares: On November 15, 2016, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") acquired 4,750,569 shares of Common Stock for an aggregate purchase price of $417,099.96 through the exercise of a warrant (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the "2014 Warrant"). Following such exercise, no shares of Common Stock remain issuable upon exercise of the 2014 Warrant.

F1 · balance_after: On November 15, 2016, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") acquired 4,750,569 shares of Common Stock for an aggregate purchase price of $417,099.96 through the exercise of a warrant (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the "2014 Warrant"). Following such exercise, no shares of Common Stock remain issuable upon exercise of the 2014 Warrant.

F4 · ownership.direct: These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd ("Mayne International") and Mayne Pharma Group Limited ("Mayne Group"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer.

SEC source: 0001144204-16-134828 · v453196_4.xml · nonDerivative · entry 3

Mayne Pharma Ventures Pty Ltd · CIK 0001611535 · 10% owner

Mayne Pharma International Pty Ltd · CIK 0001611534 · 10% owner

Mayne Pharma Group Ltd · CIK 0001560183 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,506,132

F3 · kind: On November 15, 2016, Mayne Ventures acquired 4,860,000 shares of Common Stock for an aggregate purchase price of $583,200 through the partial exercise of a warrant (at a per share exercise price of $0.12) that was issued by the Issuer to Mayne Ventures on May 25, 2016 (the "2016 Warrant"). 23,504,236 shares of Common Stock remain issuable upon exercise of the 2016 Warrant. The 2016 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time on or prior to May 25, 2021.

F3 · price: On November 15, 2016, Mayne Ventures acquired 4,860,000 shares of Common Stock for an aggregate purchase price of $583,200 through the partial exercise of a warrant (at a per share exercise price of $0.12) that was issued by the Issuer to Mayne Ventures on May 25, 2016 (the "2016 Warrant"). 23,504,236 shares of Common Stock remain issuable upon exercise of the 2016 Warrant. The 2016 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time on or prior to May 25, 2021.

F4 · ownership.direct: These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd ("Mayne International") and Mayne Pharma Group Limited ("Mayne Group"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer.

SEC source: 0001144204-16-134828 · v453196_4.xml · nonDerivative · entry 2

Mayne Pharma Ventures Pty Ltd · CIK 0001611535 · 10% owner

Mayne Pharma International Pty Ltd · CIK 0001611534 · 10% owner

Mayne Pharma Group Ltd · CIK 0001560183 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 192,646,132

F2 · kind: On November 15, 2016, Mayne Ventures acquired 333 shares of Common Stock for an aggregate purchase price of $24.98 through the exercise of a warrant (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015 (the "2015 Warrant"). No shares of Common Stock remain issuable upon exercise of the 2015 Warrant.

F2 · price: On November 15, 2016, Mayne Ventures acquired 333 shares of Common Stock for an aggregate purchase price of $24.98 through the exercise of a warrant (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015 (the "2015 Warrant"). No shares of Common Stock remain issuable upon exercise of the 2015 Warrant.

F4 · ownership.direct: These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd ("Mayne International") and Mayne Pharma Group Limited ("Mayne Group"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer.

SEC source: 0001144204-16-134828 · v453196_4.xml · nonDerivative · entry 1

Mayne Pharma Ventures Pty Ltd · CIK 0001611535 · 10% owner

Mayne Pharma International Pty Ltd · CIK 0001611534 · 10% owner

Mayne Pharma Group Ltd · CIK 0001560183 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 192,645,799

F1 · kind: On November 15, 2016, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") acquired 4,750,569 shares of Common Stock for an aggregate purchase price of $417,099.96 through the exercise of a warrant (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the "2014 Warrant"). Following such exercise, no shares of Common Stock remain issuable upon exercise of the 2014 Warrant.

F1 · price: On November 15, 2016, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") acquired 4,750,569 shares of Common Stock for an aggregate purchase price of $417,099.96 through the exercise of a warrant (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the "2014 Warrant"). Following such exercise, no shares of Common Stock remain issuable upon exercise of the 2014 Warrant.

F4 · ownership.direct: These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd ("Mayne International") and Mayne Pharma Group Limited ("Mayne Group"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer.

SEC source: 0001144204-16-132226 · v452354_4.xml · derivative · entry 4

Mayne Pharma Ventures Pty Ltd · CIK 0001611535 · 10% owner

Mayne Pharma International Pty Ltd · CIK 0001611534 · 10% owner

Mayne Pharma Group Ltd · CIK 0001560183 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 333

Underlying: Common Stock · 33,333,000 shares

Expires not disclosed

F2 · security: On November 4, 2016, Mayne Ventures acquired 33,333,000 shares of Common Stock for an aggregate purchase price of $2,499,975 through the partial exercise of a warrant to purchase 33,333,333 shares of Common Stock (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015. 333 shares of Common Stock remain issuable upon exercise of the 2015 Warrant. The 2015 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to May 15, 2020.

F2 · kind: On November 4, 2016, Mayne Ventures acquired 33,333,000 shares of Common Stock for an aggregate purchase price of $2,499,975 through the partial exercise of a warrant to purchase 33,333,333 shares of Common Stock (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015. 333 shares of Common Stock remain issuable upon exercise of the 2015 Warrant. The 2015 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to May 15, 2020.

F2 · shares: On November 4, 2016, Mayne Ventures acquired 33,333,000 shares of Common Stock for an aggregate purchase price of $2,499,975 through the partial exercise of a warrant to purchase 33,333,333 shares of Common Stock (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015. 333 shares of Common Stock remain issuable upon exercise of the 2015 Warrant. The 2015 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to May 15, 2020.

F2 · price: On November 4, 2016, Mayne Ventures acquired 33,333,000 shares of Common Stock for an aggregate purchase price of $2,499,975 through the partial exercise of a warrant to purchase 33,333,333 shares of Common Stock (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015. 333 shares of Common Stock remain issuable upon exercise of the 2015 Warrant. The 2015 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to May 15, 2020.

F2 · derivative.exercise_date: On November 4, 2016, Mayne Ventures acquired 33,333,000 shares of Common Stock for an aggregate purchase price of $2,499,975 through the partial exercise of a warrant to purchase 33,333,333 shares of Common Stock (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015. 333 shares of Common Stock remain issuable upon exercise of the 2015 Warrant. The 2015 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to May 15, 2020.

F2 · derivative.expiration_date: On November 4, 2016, Mayne Ventures acquired 33,333,000 shares of Common Stock for an aggregate purchase price of $2,499,975 through the partial exercise of a warrant to purchase 33,333,333 shares of Common Stock (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015. 333 shares of Common Stock remain issuable upon exercise of the 2015 Warrant. The 2015 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to May 15, 2020.

F2 · derivative.underlying_shares: On November 4, 2016, Mayne Ventures acquired 33,333,000 shares of Common Stock for an aggregate purchase price of $2,499,975 through the partial exercise of a warrant to purchase 33,333,333 shares of Common Stock (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015. 333 shares of Common Stock remain issuable upon exercise of the 2015 Warrant. The 2015 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to May 15, 2020.

F2 · balance_after: On November 4, 2016, Mayne Ventures acquired 33,333,000 shares of Common Stock for an aggregate purchase price of $2,499,975 through the partial exercise of a warrant to purchase 33,333,333 shares of Common Stock (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015. 333 shares of Common Stock remain issuable upon exercise of the 2015 Warrant. The 2015 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to May 15, 2020.

F3 · ownership.direct: These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd ("Mayne International") and Mayne Pharma Group Limited ("Mayne Group"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer.

SEC source: 0001144204-16-132226 · v452354_4.xml · derivative · entry 3

Mayne Pharma Ventures Pty Ltd · CIK 0001611535 · 10% owner

Mayne Pharma International Pty Ltd · CIK 0001611534 · 10% owner

Mayne Pharma Group Ltd · CIK 0001560183 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,750,569

Underlying: Common Stock · 5,500,000 shares

Expires not disclosed

F1 · security: On November 4, 2016, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") acquired 5,500,000 shares of Common Stock for an aggregate purchase price of $482,900 through the partial exercise of a warrant to purchase 10,250,569 shares of Common Stock (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the "2014 Warrant"). Following such partial exercise, 4,750,569 shares of Common Stock remain issuable upon exercise of the 2014 Warrant. The 2014 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to June 24, 2019.

F1 · kind: On November 4, 2016, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") acquired 5,500,000 shares of Common Stock for an aggregate purchase price of $482,900 through the partial exercise of a warrant to purchase 10,250,569 shares of Common Stock (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the "2014 Warrant"). Following such partial exercise, 4,750,569 shares of Common Stock remain issuable upon exercise of the 2014 Warrant. The 2014 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to June 24, 2019.

F1 · shares: On November 4, 2016, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") acquired 5,500,000 shares of Common Stock for an aggregate purchase price of $482,900 through the partial exercise of a warrant to purchase 10,250,569 shares of Common Stock (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the "2014 Warrant"). Following such partial exercise, 4,750,569 shares of Common Stock remain issuable upon exercise of the 2014 Warrant. The 2014 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to June 24, 2019.

F1 · price: On November 4, 2016, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") acquired 5,500,000 shares of Common Stock for an aggregate purchase price of $482,900 through the partial exercise of a warrant to purchase 10,250,569 shares of Common Stock (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the "2014 Warrant"). Following such partial exercise, 4,750,569 shares of Common Stock remain issuable upon exercise of the 2014 Warrant. The 2014 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to June 24, 2019.

F1 · derivative.exercise_date: On November 4, 2016, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") acquired 5,500,000 shares of Common Stock for an aggregate purchase price of $482,900 through the partial exercise of a warrant to purchase 10,250,569 shares of Common Stock (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the "2014 Warrant"). Following such partial exercise, 4,750,569 shares of Common Stock remain issuable upon exercise of the 2014 Warrant. The 2014 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to June 24, 2019.

F1 · derivative.expiration_date: On November 4, 2016, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") acquired 5,500,000 shares of Common Stock for an aggregate purchase price of $482,900 through the partial exercise of a warrant to purchase 10,250,569 shares of Common Stock (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the "2014 Warrant"). Following such partial exercise, 4,750,569 shares of Common Stock remain issuable upon exercise of the 2014 Warrant. The 2014 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to June 24, 2019.

F1 · derivative.underlying_shares: On November 4, 2016, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") acquired 5,500,000 shares of Common Stock for an aggregate purchase price of $482,900 through the partial exercise of a warrant to purchase 10,250,569 shares of Common Stock (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the "2014 Warrant"). Following such partial exercise, 4,750,569 shares of Common Stock remain issuable upon exercise of the 2014 Warrant. The 2014 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to June 24, 2019.

F1 · balance_after: On November 4, 2016, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") acquired 5,500,000 shares of Common Stock for an aggregate purchase price of $482,900 through the partial exercise of a warrant to purchase 10,250,569 shares of Common Stock (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the "2014 Warrant"). Following such partial exercise, 4,750,569 shares of Common Stock remain issuable upon exercise of the 2014 Warrant. The 2014 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to June 24, 2019.

F3 · ownership.direct: These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd ("Mayne International") and Mayne Pharma Group Limited ("Mayne Group"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer.

SEC source: 0001144204-16-132226 · v452354_4.xml · nonDerivative · entry 2

Mayne Pharma Ventures Pty Ltd · CIK 0001611535 · 10% owner

Mayne Pharma International Pty Ltd · CIK 0001611534 · 10% owner

Mayne Pharma Group Ltd · CIK 0001560183 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,895,230

F2 · kind: On November 4, 2016, Mayne Ventures acquired 33,333,000 shares of Common Stock for an aggregate purchase price of $2,499,975 through the partial exercise of a warrant to purchase 33,333,333 shares of Common Stock (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015. 333 shares of Common Stock remain issuable upon exercise of the 2015 Warrant. The 2015 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to May 15, 2020.

F2 · price: On November 4, 2016, Mayne Ventures acquired 33,333,000 shares of Common Stock for an aggregate purchase price of $2,499,975 through the partial exercise of a warrant to purchase 33,333,333 shares of Common Stock (at a per share exercise price of $0.075) that was issued by the Issuer to Mayne Ventures on May 15, 2015. 333 shares of Common Stock remain issuable upon exercise of the 2015 Warrant. The 2015 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to May 15, 2020.

F3 · ownership.direct: These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd ("Mayne International") and Mayne Pharma Group Limited ("Mayne Group"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer.

SEC source: 0001144204-16-132226 · v452354_4.xml · nonDerivative · entry 1

Mayne Pharma Ventures Pty Ltd · CIK 0001611535 · 10% owner

Mayne Pharma International Pty Ltd · CIK 0001611534 · 10% owner

Mayne Pharma Group Ltd · CIK 0001560183 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 154,562,230

F1 · kind: On November 4, 2016, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") acquired 5,500,000 shares of Common Stock for an aggregate purchase price of $482,900 through the partial exercise of a warrant to purchase 10,250,569 shares of Common Stock (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the "2014 Warrant"). Following such partial exercise, 4,750,569 shares of Common Stock remain issuable upon exercise of the 2014 Warrant. The 2014 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to June 24, 2019.

F1 · price: On November 4, 2016, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") acquired 5,500,000 shares of Common Stock for an aggregate purchase price of $482,900 through the partial exercise of a warrant to purchase 10,250,569 shares of Common Stock (at a per share exercise price of $0.0878) that was issued by the Issuer to Mayne Ventures on June 24, 2014 (the "2014 Warrant"). Following such partial exercise, 4,750,569 shares of Common Stock remain issuable upon exercise of the 2014 Warrant. The 2014 Warrant may be exercised, in whole or in part, by Mayne Ventures at any time prior to June 24, 2019.

F3 · ownership.direct: These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd ("Mayne International") and Mayne Pharma Group Limited ("Mayne Group"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer.